Journal
JOURNAL OF BIOCHEMISTRY
Volume 149, Issue 3, Pages 331-336Publisher
OXFORD UNIV PRESS
DOI: 10.1093/jb/mvq147
Keywords
Barbiturates; BAS02104951; Protein kinase C epsilon; Protein kinase C eta; RACK2
Categories
Funding
- Austrian Science Fund [P16477-B12]
- European Commission, European Union [LSHB-CT-2004-503467]
- Austrian Science Fund (FWF) [P16477] Funding Source: Austrian Science Fund (FWF)
Ask authors/readers for more resources
Protein kinase C (PKC) is a family of at least 10 isozymes involved in the activation of different signal transduction pathways. The exact function of these isozymes is not known at present. Isozyme-selective inhibitors would be important to explain the function of the different PKCs and are anticipated to have pharmaceutical potential. Here we report that the small organic molecule BAS 02104951 [5-(1,3-benzodioxol-5-ylmethylene)-1-(phenylmethyl)-2,4,6(1H,3H,5H)-pyrimidinetrion], a barbituric acid derivative, inhibited PKC eta and PKC epsilon in vitro (IC50 18 and 36 mu M, respectively). BAS 02104951 also inhibited the interaction of PKC epsilon with its adaptor protein receptor for activated C-kinase 2 (RACK2) (IC50 28.5 mu M). BAS 02104951 also inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced Elk-1 phosphorylation in HeLa cells, translocation of PKC epsilon and PKC eta to the membrane following treatment of PC3 cells with TPA. The compound did not inhibit the proliferation of PC3 and HeLa cells. BAS 02104951 can be used as selective inhibitor of PKC epsilon in cells not expressing PKC eta and may serve as a basis for the rational development of a selective inhibitor of PKC epsilon or PKC eta, or for an inhibitor of the PKC epsilon/RACK2 interaction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available